Myasthenia Gravis

Neurology
13
Pipeline Programs
12
Companies
19
Clinical Trials
8 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
6
0
3
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 18 programs with unclassified modality

On Market (1)

Approved therapies currently available

UP
RYSTIGGOApproved
rozanolixizumab
UCB Pharma
Neonatal Fc Receptor Blocker [EPC]subcutaneous2023

Competitive Landscape

9 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
4 programs
1
1
RozanolixizumabPhase 4Monoclonal Antibody1 trial
UCB7665Phase 21 trial
Social media recruitmentN/A1 trial
Social media recruitmentN/A1 trial
Active Trials
NCT06381284Completed215Est. Mar 2025
NCT06866483Recruiting1,000Est. Dec 2025
NCT03052751Completed43Est. Aug 2018
+1 more trials
CSL Behring
CSL BehringIL - Bradley
3 programs
1
1
1
Human normal immunoglobulin GPhase 31 trial
HIZENTRA ®Phase 21 trial
Subcutaneous immunoglobulinsPhase 11 trial
Active Trials
NCT01828294Terminated4Est. Dec 2017
NCT02100969Completed23Est. Jan 2018
NCT02774239Completed26Est. Oct 2022
NMD Pharma
NMD PharmaDenmark - Aarhus
2 programs
1
1
PyridostigminePhase 31 trial
NMD670Phase 21 trial
Active Trials
NCT06414954Recruiting84Est. May 2026
NCT05919407Unknown24Est. Sep 2024
Astellas
AstellasChina - Shenyang
1 program
1
Tacrolimus capsulePhase 31 trial
Active Trials
NCT01325571Completed83Est. May 2014
argenx
argenxBelgium - Zwijnaarde
4 programs
1
ARGX-113Phase 21 trial
EfgartigimodN/A1 trial
Efgartigimod IVN/A1 trial
efgartigimodN/A1 trial
Active Trials
NCT06299748Recruiting279Est. Dec 2033
NCT07294170Recruiting70Est. Mar 2028
NCT06298565Recruiting680Est. Jun 2034
+1 more trials
Grifols
GrifolsNEW YORK, NY
1 program
1
IGIV-CPhase 21 trial
Active Trials
NCT02473965CompletedEst. Feb 2019
Immunovant
ImmunovantDURHAM, NC
1 program
1
RVT-1401Phase 21 trial
Active Trials
NCT03863080CompletedEst. Dec 2020
COUR Pharmaceuticals
1 program
1
CNP-106Phase 1/21 trial
Active Trials
NCT06106672RecruitingEst. Aug 2026
Alliance Pharmaceuticals
2 programs
Immune Profiles in Myasthenia GravisN/A1 trial
Myasthenia Gravis Registry in ChinaN/A1 trial
Active Trials
NCT05095103Unknown163Est. Apr 2024
NCT06241521Recruiting1,500Est. Jan 2035

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
UCB PharmaRozanolixizumab
NMD PharmaPyridostigmine
CSL BehringHuman normal immunoglobulin G
AstellasTacrolimus capsule
NMD PharmaNMD670
ImmunovantRVT-1401
UCB PharmaUCB7665
argenxARGX-113
GrifolsIGIV-C
CSL BehringHIZENTRA ®
COUR PharmaceuticalsCNP-106
CSL BehringSubcutaneous immunoglobulins
argenxEfgartigimod IV
UCB PharmaSocial media recruitment
argenxefgartigimod

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 4,258 patients across 19 trials

NCT07246564UCB PharmaRozanolixizumab

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

Start: Dec 2025Est. completion: Oct 202740 patients
Phase 4Recruiting
NCT05919407NMD PharmaPyridostigmine

Pyridostigmine and Amifampridine for Myasthenia Gravis

Start: Mar 2023Est. completion: Sep 202424 patients
Phase 3Unknown
NCT02774239CSL BehringHuman normal immunoglobulin G

A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)

Start: Oct 2014Est. completion: Oct 202226 patients
Phase 3Completed
NCT01325571AstellasTacrolimus capsule

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis

Start: Mar 2011Est. completion: May 201483 patients
Phase 3Completed
NCT06414954NMD PharmaNMD670

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

Start: May 2024Est. completion: May 202684 patients
Phase 2Recruiting
NCT03863080ImmunovantRVT-1401

A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

Start: May 2019Est. completion: Dec 2020
Phase 2Completed
NCT03052751UCB PharmaUCB7665

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

Start: May 2017Est. completion: Aug 201843 patients
Phase 2Completed
NCT02965573argenxARGX-113

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Start: Dec 2016Est. completion: Oct 201724 patients
Phase 2Completed
NCT02473965GrifolsIGIV-C

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Start: Jun 2015Est. completion: Feb 2019
Phase 2Completed
NCT02100969CSL BehringHIZENTRA ®

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

Start: May 2015Est. completion: Jan 201823 patients
Phase 2Completed
NCT06106672COUR PharmaceuticalsCNP-106

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Start: May 2024Est. completion: Aug 2026
Phase 1/2Recruiting
NCT01828294CSL BehringSubcutaneous immunoglobulins

Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis

Start: Oct 2011Est. completion: Dec 20174 patients
Phase 1Terminated
NCT07294170argenxEfgartigimod IV

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Start: Dec 2025Est. completion: Mar 202870 patients
N/ARecruiting
NCT06866483UCB PharmaSocial media recruitment

Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment

Start: Feb 2025Est. completion: Dec 20251,000 patients
N/ARecruiting
NCT06298565argenxefgartigimod

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

Start: Nov 2024Est. completion: Jun 2034680 patients
N/ARecruiting
NCT06381284UCB PharmaSocial media recruitment

Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment

Start: Mar 2024Est. completion: Mar 2025215 patients
N/ACompleted
NCT06241521Alliance PharmaceuticalsMyasthenia Gravis Registry in China

Myasthenia Gravis Registry in China

Start: Feb 2024Est. completion: Jan 20351,500 patients
N/ARecruiting
NCT06299748argenxEfgartigimod

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

Start: Nov 2023Est. completion: Dec 2033279 patients
N/ARecruiting
NCT05095103Alliance PharmaceuticalsImmune Profiles in Myasthenia Gravis

Immune Profiles in Myasthenia Gravis

Start: Oct 2021Est. completion: Apr 2024163 patients
N/AUnknown

Related Jobs in Neurology

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
4h ago
$208K - $234K/yr

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
4h ago

Director of Medical Affairs

CoMind
Miami, FL
4h ago

Director of Finance

CoMind
London, UK
4h ago

Electronics Engineering Manager

CoMind
London, UK
4h ago

Director of Information Technology

Zavation Medical Products
4h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
8 actively recruiting trials targeting 4,258 patients
12 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)